Evaluation of minimal residual disease,immune cells dynamics and quality of life in bortezomib based induction therapy followed by lenalidomide maintenance for newly diagnosed patients with multiple myeloma ineligible for stem cell transplantation.

Evaluation of minimal residual disease,immune cells dynamics and quality of life in bortezomib based induction therapy followed by lenalidomide maintenance for newly diagnosed patients with multiple myeloma ineligible for stem cell transplantation. - KHSG MM14

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014197

Enrollment

Registered

2014-07-01

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Symptomatic multiple myeloma newly diagnosed by WHO criteria, are ineligible for autologous stem cell transplantation

Exclusion criteria

Exclusion criteria: patient who is not suitable for taking part in this study from the sight of the physician in charge

Design outcomes

Primary

Measure	Time frame
The colleration between the clinical efficacy of lenalidomide for multiple myeloma and the MRD, the serum concentration of cytokines, and QoL socre	—

Countries

Japan

Contacts

Public ContactToshiyuki Kitano

Kyoto university hospital Department of Hematology and Oncology

tkitano@kuhp.kyoto-u.ac.jp075-751-3152

Outcome results